NEJM editorial advocates aspirin therapy for patients with colorectal cancer risk.
This article was originally published in The Tan Sheet
Executive Summary
ASPIRIN USE RECOMMENDED FOR COLORECTAL CANCER AT-RISK POPULATION in an editorial in the Sept.7 issue of the New England Journal of Medicine by Aaron J. Marcus, MD, New York Veterans Affairs Medical Center and Cornell University Medical College. Marcus advised that "people at risk for colorectal cancer -- those with inflammatory bowel disease; breast, ovarian, or endometrial cancer; or a previous adenoma or large-bowel cancer -- should take a single aspirin tablet (325 mg) every other day, barring any contraindication to this medication."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning